Max Lataillade

2.0k total citations
50 papers, 1.3k citations indexed

About

Max Lataillade is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Max Lataillade has authored 50 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 42 papers in Virology and 9 papers in Emergency Medicine. Recurrent topics in Max Lataillade's work include HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (42 papers) and HIV/AIDS Research and Interventions (32 papers). Max Lataillade is often cited by papers focused on HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (42 papers) and HIV/AIDS Research and Interventions (32 papers). Max Lataillade collaborates with scholars based in United States, United Kingdom and Peru. Max Lataillade's co-authors include Michael J. Kozal, Jennifer Chiarella, Mark Krystal, George J. Hanna, Rong Yang, Jean‐Michel Molina, Donnie McGrath, Victoria Wirtz, Samit R. Joshi and Neelanjana Ray and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Max Lataillade

48 papers receiving 1.3k citations

Peers

Countries citing papers authored by Max Lataillade

Since Specialization

Citations

This map shows the geographic impact of Max Lataillade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Lataillade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Lataillade more than expected).

Fields of papers citing papers by Max Lataillade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Lataillade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Lataillade. The network helps show where Max Lataillade may publish in the future.

Co-authorship network of co-authors of Max Lataillade

This figure shows the co-authorship network connecting the top 25 collaborators of Max Lataillade. A scholar is included among the top collaborators of Max Lataillade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Lataillade. Max Lataillade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study 2025 ·EClinicalMedicine ·Samit R. Joshi, Mar Masiá, Essack Mitha, Antonella Castagna, Ezequiel Córdova, Moti Ramgopal, (unknown), S. Karthika, J Oyee, (unknown), Brian Wynne, Max Lataillade	0
2	Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 2023 ·Infectious Diseases and Therapy ·Judith A. Aberg, (unknown), (unknown), (unknown), (unknown), Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy Kumar, Eduardo Sprinz, Margaret Gartland, (unknown), Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio	7
3	Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants 2023 ·British Journal of Clinical Pharmacology ·Ying Zhang, Mark Johnson, Samit R. Joshi, (unknown), (unknown), (unknown), (unknown), Martin Gartland, Max Lataillade	1
4	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 2022 ·Clinical Infectious Diseases ·Christoph D. Spinner, Franco Felizarta, Giuliano Rizzardini, Patrick Philibert, Essack Mitha, Peré Domingo, Christoph Stephan, (unknown), (unknown), (unknown), Teodora Pene Dumitrescu, Jerry Jeffrey, (unknown), (unknown), (unknown), Mark R. Johnson, Martin Gartland, Samit R. Joshi, Max Lataillade	15
5	A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection 2022 ·Antiviral Therapy ·Mark Krystal, (unknown), Daren Austin, (unknown), (unknown), Max Lataillade, Judah Abberbock, Mark Baker, Peter Ackerman	1
6	A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants 2021 ·Antimicrobial Agents and Chemotherapy ·Teodora Pene Dumitrescu, Samit R. Joshi, (unknown), (unknown), Mark Johnson, (unknown), Eric I. Zimmerman, Lindsey O. Webster, (unknown), Max Lataillade, Sherene Min	12
7	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study 2019 ·PLoS ONE ·(unknown), Sharon Zhang, Neelanjana Ray, Brett R. Beno, Alicia Regueiro‐Ren, Samit R. Joshi, Mark I. Cockett, Mark Krystal, Max Lataillade	14
8	Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial 2018 ·PLoS ONE ·Javier O Morales-Ramirez, Johannes R. Bogner, Jean‐Michel Molina, Johan Lombaard, Ira B. Dicker, David Stock, (unknown), Margaret Gartland, Teodora Pene Dumitrescu, Sherene Min, Cyril Llamoso, Samit R. Joshi, Max Lataillade	31
9	Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors 2016 ·PLoS Pathogens ·Zeyu Lin, Joseph L. Cantone, Hao Lu, Beata Nowicka-Sans, (unknown), Yuan Tian, Hong Yang, Zheng Liu, Dieter M. Drexler, Alicia Regueiro‐Ren, Nicholas A. Meanwell, Mark I. Cockett, Mark Krystal, Max Lataillade, Ira B. Dicker	16
10	Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age 2015 ·The Pediatric Infectious Disease Journal ·Noris Pavía-Ruz, (unknown), Xavier Sáez‐Llorens, Torsak Bunupuradah, (unknown), Rong Yang, (unknown), Mark Krystal, Max Lataillade, Daniel Seekins, (unknown)	4
11	Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial 2015 ·The Lancet HIV ·Jacob Lalezari, Gulam Latiff, Cynthia Brinson, Juan Echevarría, (unknown), Johannes R. Bogner, Melanie Thompson, Jan Fourie, (unknown), (unknown), Marcelo Martins, (unknown), David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade	50
12	Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis 2014 ·Journal of the International AIDS Society ·Jacob Lalezari, Gulam Latiff, Cynthia Brinson, Juan Echevarría, (unknown), Johannes R. Bogner, David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade	4
13	540HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis 2014 ·Open Forum Infectious Diseases ·Cynthia Brinson, Jacob Lalezari, Gulam Latiff, Melanie Thompson, Juan Echevarría, (unknown), David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade	1
14	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 2013 ·Journal of Antimicrobial Chemotherapy ·Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, (unknown), Hua Fang, Fan Li, Matthew D. Healy, David R. Langley, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal	55
15	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Neelanjana Ray, Carey Hwang, Matthew D. Healy, Jeannette M. Whitcomb, Max Lataillade, Megan Wind‐Rotolo, Mark Krystal, George J. Hanna	39
16	Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing 2012 ·PLoS ONE ·Max Lataillade, Jennifer Chiarella, Rong Yang, (unknown), Jonathan Uy, Daniel Seekins, Birgitte B. Simen, Elizabeth St. John, (unknown), Michael J. Kozal	31
17	A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results 2012 ·HIV Clinical Trials ·Michael J. Kozal, Sergio Lupo, Edwin DeJesus, Jean‐Michel Molina, Cheryl McDonald, François Raffi, Jorge Benetucci, Marco Mancini, Rong Yang, Victoria Wirtz, (unknown), Jenny Zhang, Li Zhu, Dilek Arikan, Awny Farajallah, Bach‐Yen Nguyen, Randi Y. Leavitt, Donnie McGrath, Max Lataillade, (unknown)	70
18	Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría, Ploenchan Chetchotisakd, (unknown), (unknown), Graeme Moyle, Marco Mancini, (unknown), Rong Yang, Victoria Wirtz, Max Lataillade, Judith Absalon, Donnie McGrath	183
19	The Hunt for HIV-1 Integrase Inhibitors 2006 ·AIDS Patient Care and STDs ·Max Lataillade, Michael J. Kozal	44
20	Concurrent Outbreak of Multidrug-Resistant and Susceptible Subclones of Acinetobacter baumannii Affecting Different Wards of a Single Hospital 2005 ·Infection Control and Hospital Epidemiology ·Joel N. Maslow, (unknown), (unknown), Max Lataillade	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact